SCHEDULE: Nantahala Capital Discloses 6.37% Stake in Korro Bio

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 6.37% beneficial ownership stake in Korro Bio, Inc. as of December 31, 2025.

Summary

• Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack (the "Reporting Persons") collectively reported beneficial ownership of 600,000 shares of Korro Bio, Inc. Common Stock.
• This ownership represents 6.37% of Korro Bio, Inc.'s outstanding common stock.
• The Reporting Persons share both voting and dispositive power over all 600,000 shares.
• Nantahala Capital Management, LLC is classified as an investment adviser, while Wilmot B. Harkey and Daniel Mack are identified as control persons.
• The filing was made under Rule 13d-1(b) of the Securities Exchange Act of 1934, indicating an institutional investor filing in the ordinary course of business.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant stake by an institutional investor like Nantahala Capital Management can be interpreted as a vote of confidence in Korro Bio's value proposition and future prospects.

Positives

• A significant institutional investor, Nantahala Capital Management, has taken a substantial stake in Korro Bio, indicating potential confidence in the company's future prospects.
• The acquisition of shares was stated to be in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Negatives

• NA

Risks

• NA

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Korro Bio, Inc.'s future performance or operations.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

StockSavvy.ai notes that institutional investment in biotechnology companies like Korro Bio often signals a belief in the long-term potential of their research and development pipelines. While this filing does not provide specific industry analysis, a new significant stake from an investment manager can draw attention to the company within the competitive biotech landscape.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially attract further institutional interest, which could positively influence share price.
• Company Management: Awareness of a significant institutional holder may influence strategic decisions and communication with the investment community.

Next Steps

• NA

Key Dates

Recommendation

A Schedule 13G filing primarily discloses beneficial ownership and does not provide sufficient operational or financial data to warrant a 'buy' or 'sell' recommendation. However, the presence of a significant institutional investor like Nantahala Capital Management holding a 6.37% stake suggests a level of institutional confidence, making a 'hold' recommendation appropriate for existing investors while encouraging further due diligence into Korro Bio's fundamentals.

Keywords

Korro Bio, Nantahala Capital Management, Beneficial Ownership, Institutional Investment, SEC Filing, Common Stock, Biotechnology, Investment Adviser